Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses the benefits that biosimilars have in terms of patient access.
Transcript:
Perhaps, for the developing countries, biosimilars are a way to get more people on therapy. I’m thinking of China, thinking of India, thinking of Mexico and the Middle East countries. In these health systems, I think a lot of people are pending getting these medications, so this is a way to help people in these countries to be on therapy.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.